Yaewon Yang

Dr. Yaewon Yang

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Journal of Gastric Cancer
Verified
Journal Article
Open access
JYJieun Yun
Jieun Yun
SHSang-Bae Han
Sang-Bae Han
HKHong Jun Kim
Hong Jun Kim
SGSe-Il Go
Se-Il Go
WLWon Sup Lee
Won Sup Lee
HHHye Sook Han
Hye Sook Han
Yun J, et al. J Gastric Cancer. 2019 Apr;19:e27. https://doi.org/10.5230/jgc.2019.19.e27

1 November 2021 in European Journal of Cancer
Verified
Journal Article
Closed access
SGSe-Il Go
Se-Il Go
SLSang-Cheol Lee
Sang-Cheol Lee
WBWoo Kyun Bae
Woo Kyun Bae
DZDae Young Zang
Dae Young Zang
HLHyun Woo Lee
Hyun Woo Lee
JKJung Hun Kang
Jung Hun Kang

1 January 2025 in Journal of Gastric Cancer
Verified
Journal Article
Open access
PDF file
SSSeung-Myoung Son
Seung-Myoung Son
CWChang Gok Woo
Chang Gok Woo
OLOk-Jun Lee
Ok-Jun Lee
SLSun Kyung Lee
Sun Kyung Lee
MCMinkwan Cho
Minkwan Cho
HHHye Sook Han
Hye Sook Han
Son SM, et al. J Gastric Cancer. 2024 Dec;25:e2. https://doi.org/10.5230/jgc.2025.25.e2

1 January 2025 in Journal of Gastric Cancer
Verified
Journal Article
Open access
PDF file
HKHongsik Kim
Hongsik Kim
MKMinsuk Kwon
Minsuk Kwon
SLSun Kyung Lee
Sun Kyung Lee
SSSeung-Myoung Son
Seung-Myoung Son
OLOk-Jun Lee
Ok-Jun Lee
HHHye Sook Han
Hye Sook Han
Kim H, et al. J Gastric Cancer. 2025 Oct;25:e46. https://doi.org/10.5230/jgc.2025.25.e46

21 July 2016 in BMC Cancer
Verified
Journal Article
Open access
PDF file
YYYaewon Yang
Yaewon Yang
SISeock-Ah Im
Seock-Ah Im
BKBhumsuk Keam
Bhumsuk Keam
KLKyung-Hun Lee
Kyung-Hun Lee
TKTae-Yong Kim
Tae-Yong Kim
DNDong-Young Noh
Dong-Young Noh
Neoadjuvant chemotherapy (NAC) is a standard treatment for stage II/III breast cancer patients, and response to NAC is a useful prognostic marker. Since its introduction, 6–8 cycles of NAC has become the standard regimen to improve the outcome of these patients. The purpose of this study is to evaluate the prognostic impact of the American Joint Committee on Cancer (AJCC) response criteria and this tool’s usefulness in four different breast cancer subtypes. We conducted a retrospective cohort study of clinical stage II/III breast cancer patients who received NAC of more than 6 cycles. Response after NAC and the clinicopathological factors were reviewed. AJCC response criteria for NAC were adopted from the AJCC Manual, 7th edition: complete response (CR), partial response (PR), and no response (NR). A total of 183 patients were enrolled; 22 (12.0 %), 123 (67.2 %), and 38 (20.8 %) patients showed CR, PR, and NR, respectively. The AJCC response was significantly associated with relapse-free survival (RFS) (P < 0.001), whereas pathologic CR (pCR), the current gold standard for response evaluation for NAC, was not (P = 0.140). AJCC response was a significant prognostic factor for RFS in all four breast cancer subtypes, namely luminal A (P = 0.006), luminal B (P = 0.001), HER-2 enriched (P = 0.039), and triple-negative breast cancer (P = 0.035). The AJCC response criteria represent a simple and easily reproducible tool for response evaluation of NAC patients and a useful clinical prognostic marker for RFS. These criteria also have a prognostic impact in all four breast cancer subtypes, including luminal A in which pCR has a limited role.

29 August 2024 in ESMO Open
Verified
Journal Article
Open access
EKE.J. Kang
E.J. Kang
YYYaewon Yang
Yaewon Yang
SLS. Lee
S. Lee
YKY.J. Kim
Y.J. Kim
SLS.M. Lim
S.M. Lim
KLKihyeong Lee
Kihyeong Lee
We evaluated the efficacy and safety of tepotinib in patients with various solid cancers harboring MET exon 14 skipping mutation (METex14) or MET gene amplification. A phase II, multicenter study was conducted in patients with advanced or metastatic solid cancers who progressed after standard treatment, harboring either METex14 or MET amplification detected in tissue-based next-generation sequencing (NGS). The primary endpoint was objective response rate (ORR). For exploratory analyses, we analyzed the gene profiles using plasma NGS test. Thirty-five patients were enrolled. The ORR was 57.6% for all patients, 52.2% for those with METex14, and 70% for those with MET amplification. Median progression-free survival (PFS) was 8 months [95% confidence interval (CI) 4.5-11.5 months] and median overall survival (OS) was 14 months (95% CI 7.8-20.2 months) in all patients. For patients with non-small-cell lung cancer with METex14, the median PFS was 9 months (95% CI 4.7-13.4 months) and the median OS was 17 months [95% CI not applicable (NA)-NA]. For patients with MET amplification, the median PFS was 7 months (95% CI 1.5-12.5 months) and the median OS was 10 months (95% CI 5.8-14.2 months). The ORR of patients with MET dysregulation detected by plasma NGS was 72.2%, whereas the ORR was 30% in those without detection. The most common adverse events were peripheral edema, asthenia, transaminase elevation, and anorexia, mostly grade 1 or 2. Tepotinib demonstrated consistent antitumor activity in patients with METex14, and promising antitumor activity in various cancers with MET amplification. Detection of MET dysregulation by plasma NGS may predict the response to tepotinib.